Arabic Arabic English English French French German German
dark

Secarna Pharmaceuticals and Achilles Therapeutics Sign Research, Option and License Agreement to Develop Optimized T Cell Therapies

Secarna Pharmaceuticals GmbH & Co. KG today announced that the Company has entered into a research, option and license agreement with Achilles Therapeutics UK Limited (“Achilles”), a member of the Achilles Therapeutics plc (NASDAQ:ACHL) group of companies, in the field of immune oncology. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Schrödinger Reports Third Quarter 2021 Financial Results and Provides Company Update

Next Post

Texas Based 4E Therapeutics Awarded National Institutes of Health Research Grant to Develop Non-Opioid Treatment for Pain to End Addiction

Related Posts
Total
0
Share